• Home>
  • Stocks>
  • Glenmark Pharmaceuticals Ltd Share Price
Glenmark Pharmaceuticals Ltd share price logo

Glenmark Pharmaceuticals Ltd Share Price

(GLENMARK)

Mid Cap

Healthcare Sector

₹1384.4▲1.65%

as on 04:01PM, 29 Apr 2025

bell
The current prices are delayed by 15 mins, login to check live prices.

Option Chain

Glenmark Pharmaceuticals Ltd Performance

  • Day's Low

    Day's High

    ₹1,380
    Day's Price Range
    ₹1,416.5

  • 52 Week's Low

    52 Week's High

    ₹985.2
    52-Week Price Range
    ₹1,830.95
1 Month Return-8.27 %
3 Month Return-4.45 %
1 Year Return+ 30.95 %
Previous Close₹1,407.60
Open₹1,415.00
Volume3.15L
Upper Circuit₹1,548.30
Lower Circuit₹1,266.90
Market Cap₹39,066.13Cr

Glenmark Pharmaceuticals Ltd Fundamentals

P/E Ratio

-222.22

PEG Ratio

-11.7

Market Cap

₹39,066.13 Cr

P/B Ratio

1.18

EPS

-50.8

Dividend Yield

0.26

Sector

Pharmaceuticals

ROE

6.98

Glenmark Pharmaceuticals Ltd Analyst Rating

based on 12 analysts

BUY

75.00%

Buy

16.67%

Hold

8.33%

Sell

Based on 12 analysts offering long term price targets for Glenmark Pharmaceuticals Ltd. An average target of ₹1690.92

Source: S&P Global Market Intelligence

Glenmark Pharmaceuticals Ltd Share analysis

Glenmark Pharmaceuticals Ltd price forecast by 12 analysts

Upside of22.14%

High

₹2032

Target

₹1690.92

Low

₹1265

Glenmark Pharmaceuticals Ltd target price ₹1690.92, a slight upside of 22.14% compared to current price of ₹1384.4. According to 12 analysts rating.

Source: S&P Global Market Intelligence

Key events for Glenmark Pharmaceuticals Ltd

  • Glenmark's Innovation Arm to Become Self-Funded - 27 Apr, 2025

    Glenmark Pharmaceuticals plans to out-license its key cancer asset ISB-2001, enabling its innovation arm, Ichnos Glenmark Innovation, to become self-funded by the end of the year.

  • Glenmark Receives Court Clarification Amid Buy Recommendation - 24 Apr, 2025

    Glenmark Pharmaceuticals is recommended for purchase with a target price of ₹1,475. The Delhi High Court clarified that recent drug restrictions apply prospectively, benefiting the company.

  • Glenmark Pharmaceuticals Faces Spurious Drug Issue - 18 Apr, 2025

    Glenmark Pharmaceuticals is facing a serious issue as a batch of Telma 40, prescribed for high blood pressure, has been identified as spurious. The actual manufacturer claims it was not produced by them, raising concerns about drug safety.

  • Glenmark Pharmaceuticals Announces Adderall Launch Plans - 17 Apr, 2025

    Glenmark Pharmaceuticals is set to launch a generic version of Adderall in May 2025, targeting a significant ADHD market. The stock saw increased trading volume despite a slight price decline.

  • Glenmark Launches New Products Amid Trading Surge - 16 Apr, 2025

    Glenmark Pharmaceuticals Inc. plans to launch Dextroamphetamine products in May 2025 to alleviate U.S. shortages. Meanwhile, Glenmark's stock experiences a significant trading volume increase but declines in price.

  • Glenmark Faces Stock Decline Amid USFDA Recall - 09 Apr, 2025

    Glenmark Pharmaceuticals faced significant stock declines after the USFDA announced a Class-II recall of 39 drugs due to manufacturing issues, leading to a 7% drop in shares.

  • Glenmark Appoints New President Amid Market Decline - 07 Apr, 2025

    On April 7, 2025, Glenmark Pharmaceuticals appointed Anurag Mantri as President. The stock faced pressure as Indian pharma shares dropped due to US tariff comments.

  • Glenmark Shares Drop Amid Tariff Concerns - 04 Apr, 2025

    Glenmark Pharmaceuticals shares fell 4.35% to ₹1,478.00 following President Trump's warning of potential pharmaceutical tariffs, reversing previous gains. Analysts express cautious optimism despite challenges.

  • Glenmark Pharma Shares Surge on Tariff Exemption - 03 Apr, 2025

    Glenmark Pharmaceuticals' shares increased by 3.28% following the U.S. government's exemption of pharmaceuticals from a newly imposed 26% reciprocal tariff, providing relief to Indian drug manufacturers.

  • Glenmark Launches Vancomycin Injection in US Market - 01 Apr, 2025

    Glenmark Pharmaceuticals Inc. has launched Vancomycin Hydrochloride for Injection USP in various dosages, targeting a significant market opportunity worth approximately $39.3 million.

  • CDSCO Flags Spurious Batch of Telma H Drug - 30 Mar, 2025

    The CDSCO has flagged a spurious batch of Telma H, a hypertension medication manufactured by Glenmark Pharmaceuticals, along with 103 other drugs failing quality tests. The actual manufacturer confirmed the flagged batch was not produced by them.

  • Glenmark to Close Swiss Manufacturing Facility - 29 Mar, 2025

    Glenmark Pharmaceuticals announced the closure of its Switzerland-based IGI facility by July 2025. The move aims to enhance its clinical pipeline by transitioning manufacturing to established CDMOs, with no adverse impact on financials expected.

Insights on Glenmark Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 12.12% to 12.86% in Mar 2025 quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, GLENMARK has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 51.1% return, outperforming this stock by 19.7%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 46.65% of holdings in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 3.47K Cr → 3.41K Cr (in ₹), with an average decrease of 1.6% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 354.21 Cr → 347.96 Cr (in ₹), with an average decrease of 1.8% per quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 15.96% to 15.56% in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 23.51% to 23.16% in Mar 2025 quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, GLENMARK stock has moved down by -6.7%

Glenmark Pharmaceuticals Ltd Financials

Value in ₹ crore
DetailsQ'4 23Q'1 24Q'2 24Q'3 24Q'4 24
Revenue₹2,460.29Cr (-)₹3,016.01Cr (↑22.59%)₹3,223.30Cr (↑6.87%)₹3,400.50Cr (↑5.50%)₹3,301.90Cr (↓2.90%)
Net Income-₹330.82Cr (-)-₹1,214.27Cr (↑267.05%)₹340.24Cr (↓128.02%)₹354.49Cr (↑4.19%)₹348.03Cr (↓1.82%)
Net Profit Margin-13.45% (-)-40.26% (↑199.33%)10.56% (↓126.23%)10.42% (↓1.33%)10.54% (↑1.15%)
Value in ₹ crore
Details2021202220232024
Total Assets₹20,882.95Cr (-)₹23,128.70Cr (↑10.75%)₹24,799.42Cr (↑7.22%)₹27,724.16Cr (↑11.79%)
Total Liabilities₹6,073.44Cr (-)₹6,390.11Cr (↑5.21%)₹6,921.95Cr (↑8.32%)₹4,753.54Cr (↓31.33%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹1,579.12Cr (-)₹1,243.42Cr (↓21.26%)₹1,216.07Cr (↓2.20%)₹1,474.06Cr (↑21.22%)-₹495.45Cr (↓133.61%)

Glenmark Pharmaceuticals Ltd Index Inclusions

S&P BSE Momentum

₹2,059.88

0.37 (▲7.51%)

NIFTY PHARMA

₹21,676.65

-1.06 (▲-231.45%)

Nifty Midcap 100

₹54,587.95

0.27 (▲147.7%)

S&P BSE 150 MidCap

₹14,998.79

0.26 (▲38.88%)

S&P BSE 400 MidSmallCap

₹11,199.56

0.25 (▲27.99%)

BSE Healthcare

₹42,211.90

-0.81 (▲-343.75%)

Nifty LargeMidcap 250

₹15,416.05

0.1 (▲15.35%)

BSE 500

₹34,785.55

0.06 (▲19.76%)

Nifty Alpha 50

₹48,219.85

0.77 (▲367.4%)

Nifty 200

₹13,469.00

0.03 (▲4.4%)

Nifty Midcap 150

₹20,009.05

0.21 (▲42.35%)

Nifty Healthcare

₹13,992.20

-0.88 (▲-124.05%)

S&P BSE 250 LargeMidCap

₹10,387.30

0.04 (▲4.03%)

Nifty MidSmallcap 400

₹18,431.30

0.21 (▲38.8%)

BSE Mid-Cap

₹43,194.16

0.23 (▲97.15%)

Nifty 500

₹22,112.40

0.05 (▲10.55%)

Glenmark Pharmaceuticals Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
46.65%
0.00
Foreign Institutions
23.16%
0.00
Mutual Funds
12.86%
0.00
Retail Investors
15.56%
0.00
Others
1.78%
0.00

Glenmark Pharmaceuticals Ltd Key Indicators

Details20202021202220232024
Return On Equity %10.7611.7710.429.126.98
Details20202021202220232024
Return On Assets %4.044.654.071.2-5.42
Details20202021202220232024
Book Value Per Share (₹)215.14250.37322.03335.75278.11
Details20202021202220232024
Earning Per Share (₹)27.534.3835.2113.37-50.8

Glenmark Pharmaceuticals Ltd Valuation

Glenmark Pharmaceuticals Ltd in the last 5 years

  • Overview

  • Trends

Lowest (-275.05x)

December 28, 2023

Today (-222.22x)

April 29, 2025

Industry (54.77x)

April 29, 2025

Highest (95.94x)

September 14, 2023

LowHigh

Glenmark Pharmaceuticals Ltd Earnings and Dividends

  • Glenmark Pharmaceuticals Ltd Earnings Results

    Glenmark Pharmaceuticals Ltd’s net profit jumped 199.03% since last year same period to ₹347.96Cr in the Q3 2024-2025. On a quarterly growth basis, Glenmark Pharmaceuticals Ltd has generated -1.76% fall in its net profits since last 3-months.

    Read More about Earnings Results

  • Glenmark Pharmaceuticals Ltd Dividends May,2024

    In the quarter ending March 2024, Glenmark Pharmaceuticals Ltd has declared dividend of ₹2.50 - translating a dividend yield of 0.18%.

    Read More about Dividends

Glenmark Pharmaceuticals Ltd Technicals Summary

Bearish

Neutral

Bullish

Bearish

Glenmark Pharmaceuticals Ltd is currently in a Bearish trading position according to technical analysis indicators.

More on Technical Analysis

Glenmark Pharmaceuticals Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd
BUY₹39,066.13 Cr62.15%0.52-₹1,434 Cr₹11,813 Cr
Suven Pharmaceuticals Ltd
Suven Pharmaceuticals Ltd
BUY₹28,928.76 Cr133.26%0.52₹300 Cr₹1,051 Cr
Jubilant Pharmova Ltd
Jubilant Pharmova Ltd
BUY₹14,252.57 Cr31.52%0.57₹72 Cr₹6,702 Cr
Sun Pharma Advanced Research Company Ltd
Sun Pharma Advanced Research Company Ltd
NA₹4,817.52 Cr2.55%0.79-₹388 Cr₹75 Cr
Rainbow Childrens Medicare Ltd
Rainbow Childrens Medicare Ltd
BUY₹13,783.61 Cr40.3%0.68₹218 Cr₹1,296 Cr
See all

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd is an Indian pharmaceuticals company listed on the National Stock Exchange and Bombay Stock Exchange. Established in 1977, the company manufactures and distributes branded and generic formulations, active pharmaceutical ingredients (API’s) and biosimilars. It has 18 manufacturing facilities in India, 7 in the U.S., 1 in Brazil and 1 in Mexico that span across the world catering to global requirements. Glenmark has taken several steps towards achieving a healthy presence in the global markets. In addition to its product portfolio, Glenmark’s aggressive acquisition strategy and product launch activities have helped expand its market reach. The company has been awarded numerous accolades over the years, including consecutive years of being ranked amongst the top 1000 world pharmaceutical companies. It continues to be a frontrunner in providing quality and affordable healthcare solutions in India and abroad.

Revenue: ₹3,301.90Cr as on December 2024 (Q4 24)
Net Profit: ₹348.03Cr as on December 2024 (Q4 24)
Listing date: 07 Feb, 2000
Chairperson Name: Glenn Saldanha
OrganisationGlenmark Pharmaceuticals Ltd
HeadquartersMumbai
IndustryPharmaceuticals
E-voting on sharesClick here to vote

FAQs on Glenmark Pharmaceuticals Ltd

What is Glenmark Pharmaceuticals Ltd price today?

Glenmark Pharmaceuticals Ltd share price today stands at ₹1384.4, Open: ₹1415, Previous Close: ₹1407.6, High: ₹1416.5, Low: ₹1380, 52 Week High: ₹1830.95, 52 Week Low: ₹985.2.

How to Buy Glenmark Pharmaceuticals Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Glenmark Pharmaceuticals Ltd shares

What are today's traded volumes of Glenmark Pharmaceuticals Ltd?

Today's traded volume of Glenmark Pharmaceuticals Ltd(GLENMARK) is 3.15L.

What is today's market capitalisation of Glenmark Pharmaceuticals Ltd?

Today's market capitalisation of Glenmark Pharmaceuticals Ltd(GLENMARK) is ₹39066.13Cr.

What is the 52 Week High and Low Range of Glenmark Pharmaceuticals Ltd?

Glenmark Pharmaceuticals Ltd (GLENMARK)
Price
52 Week High
₹1830.95
52 Week Low
₹985.2

How much percentage Glenmark Pharmaceuticals Ltd is down from its 52 Week High?

Glenmark Pharmaceuticals Ltd (GLENMARK) share price is ₹1384.4. It is down -24.39% from its 52 Week High price of ₹1830.95

How much percentage Glenmark Pharmaceuticals Ltd is up from its 52 Week low?

Glenmark Pharmaceuticals Ltd (GLENMARK) share price is ₹1384.4. It is up 40.52% from its 52 Week Low price of ₹985.2